Drug Profile
Research programme: cancer therapeutics - Oscotec
Alternative Names: HIF 143Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Oscotec
- Class
- Mechanism of Action Epidermal growth factor inhibitors; Fms-like tyrosine kinase 3 inhibitors; Reactive oxygen species inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea (PO)
- 31 Mar 2012 Preclinical trials in Cancer in South Korea (PO) before March 2013
- 31 Mar 2012 Efficacy and toxicological data from preclinical trials in Cancer presented at the 103rd Annual Meeting of the American Association for Cancer Research (AACR-2012)